Mitsubishi UFJ Trust & Banking Corp Has $9.74 Million Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Mitsubishi UFJ Trust & Banking Corp lowered its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 12.5% during the fourth quarter, Holdings Channel reports. The fund owned 72,884 shares of the life sciences company’s stock after selling 10,367 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp’s holdings in Illumina were worth $9,739,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the company. Versant Capital Management Inc boosted its position in Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after acquiring an additional 146 shares during the period. Golden State Wealth Management LLC acquired a new stake in shares of Illumina during the fourth quarter worth approximately $32,000. Assetmark Inc. grew its position in Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock valued at $44,000 after purchasing an additional 296 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new position in Illumina during the fourth quarter valued at approximately $45,000. Finally, Lee Danner & Bass Inc. acquired a new position in Illumina in the 4th quarter valued at approximately $48,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Stock Down 2.8 %

Shares of ILMN stock opened at $80.00 on Friday. Illumina, Inc. has a 12 month low of $79.30 and a 12 month high of $156.66. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The firm has a market cap of $12.67 billion, a PE ratio of -10.42, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. The stock has a 50 day moving average of $102.80 and a 200-day moving average of $126.81.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, equities analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Piper Sandler boosted their price target on shares of Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Citigroup dropped their target price on Illumina from $130.00 to $90.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Morgan Stanley reduced their price target on Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a report on Tuesday, February 11th. HSBC downgraded Illumina from a “buy” rating to a “hold” rating and set a $100.00 price objective on the stock. in a report on Friday, February 28th. Finally, Guggenheim reduced their target price on shares of Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Friday, February 7th. One research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $140.90.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.